Loading
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$53.81
+$3.83 · +7.66%
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Previous close
$53.81
+$3.83 · +7.66%
Regular session · ET · Market data may be delayed.
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Day range
Current $53.81
52-week range
Current $53.81
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
13
Overpriced
Sentiment
63
Bullish
Risk
57
Elevated Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Day range
Current $53.81
52-week range
Current $53.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 350K USD | — | — | 700K USD | 1.42M USD |
| Cost of goods sold | 1.61M USD | — | 1.21M USD | 11.94M USD | 1.97M USD |
| Gross profit | −1.26M USD | — | −1.21M USD | −11.24M USD | −550K USD |
| Research and development | 44.72M USD | 32.34M USD | 27.8M USD | 20.84M USD | 28.64M USD |
| Selling, general, and administrative | 32.03M USD | 23.92M USD | 15.78M USD | 25.97M USD | 33.82M USD |
| Operating expenses | 75.68M USD | 56.26M USD | 42.37M USD | 46.81M USD | 62.46M USD |
| Interest income | 4.21M USD | 2.67M USD | 2.46M USD | — | — |
| Interest expense | — | — | 1.1M USD | 448K USD | 646K USD |
| Depreciation and amortization | 1.07M USD | 1.18M USD | 1.21M USD | 1.36M USD | 1.15M USD |
| Operating income | −76.94M USD | −56.26M USD | −43.57M USD | −58.06M USD | −63.01M USD |
| Net income | −72.78M USD | −53.59M USD | −42.21M USD | −58.51M USD | −63.66M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$53.20
1.13% downsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI27.91M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM24.88M0.03%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF10.88M0.01%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO8.68M0.06%13.92B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO5.37M0.03%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA5.33M0.02%21.82B USD0.03%$32.79+0.40%
iShares U.S. Medical Devices ETFIHI4.94M0.14%3.57B USD0.37%$51.74+1.25%
Invesco Dorsey Wright Healthcare Momentum ETFPTH3.33M1.16%287.29M USD0.74%$58.757+2.42%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Medical Devices ETFIHIInvesco Dorsey Wright Healthcare Momentum ETFPTHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
